PD60-12 PROGNOSTIC VALUE OF COMBINED ANALYSIS OF PRO-NPY AND ERG PROTEIN EXPRESSION IN PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Markers III1 Apr 2018PD60-12 PROGNOSTIC VALUE OF COMBINED ANALYSIS OF PRO-NPY AND ERG PROTEIN EXPRESSION IN PROSTATE CANCER Gitte Kristensen, Martin Andreas Roeder, Kasper Drimer Berg, Johanna Elversang, Birgitte Groenkaer Toft, and Klaus Brasso Gitte KristensenGitte Kristensen More articles by this author , Martin Andreas RoederMartin Andreas Roeder More articles by this author , Kasper Drimer BergKasper Drimer Berg More articles by this author , Johanna ElversangJohanna Elversang More articles by this author , Birgitte Groenkaer ToftBirgitte Groenkaer Toft More articles by this author , and Klaus BrassoKlaus Brasso More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2824AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Apart from PSA, only few biomarkers reflecting prostate cancer (PCa) biology are introduced. Discovery of new biomarkers could refine prognostication for patients at risk of biochemical failure (BF) following radical prostatectomy (RP). Neuropeptide Y (NPY) and its precursor pro-NPY may be important factors for mitogenic and angiogenic activity. High expression of pro-NPY in ERG positive tumors has previously shown to be associated with increased risk of PCa specific death in men on watchful-waiting. This study aimed to investigate if combined analysis of pro-NPY and ERG protein expression in tumor tissue were associated with BF for men undergoing RP. METHODS The study included 311 consecutive patients, who underwent RP from Jan. 1st 2002 to Dec. 31st 2005 at the Department of Urology, Rigshospitalet, Copenhagen, Denmark. Pro-NPY and ERG protein expression were analyzed using immunohistochemistry (IHC; anti-pro-NPY: HPA044572; anti-ERG: EPR3864) on tissue arrays with tumor tissue from the RP specimens. pro-NPY immunoreactivity (IR) was scored semiquantitative as low (IR negative or weak) or high (IR moderate or strong). ERG IR was scored as negative or positive. Assessment of the IHC staining was done blinded. Clinicopathological information were collected from the medical records. Risk of BF was analyzed using multiple cause-specific Cox regression and stratified cumulative incidences (Aalen-Johansen method) using competing risk assessment. Death without BF was treated as a competing event. RESULTS After median 11.6 years follow-up, 147 men experienced BF. In total, 266 patients (85.5%) had high and 45 (14.5%) had low pro-NPY IR whereas 195 (62.7%) were ERG positive and 116 (37.3%) were ERG negative. The 10-year cumulative incidence of BF was 48.7% (95% CI: 33.7-63.7) in the pro-NPY low group compared with 44.1% (95% CI: 37.9-50.4) in the pro-NPY high group. In the multiple cause-specific Cox regression analysis pro-NPY high was not found associated with BF (HR: 0.82; 95% CI 0.5-1.4; p=0.49). The 10-year cumulative incidence for BF was 48.6% (95% CI: 33.2-64.0) in the ERG negative pro-NPY low group compared with 41.8% (95% CI: 34.6-49.0) in the ERG positive pro-NPY high group. The combination of ERG positive and pro-NPY high was not associated with a risk of BF in the multiple cause-specific Cox regression analysis (HR: 1.02; 95% CI 0.6-1.7; p=0.94). CONCLUSIONS pro-NPY expression alone or combined with ERG status was not found associated with risk of BF following RP. Analyses of association with time to initiation of secondary treatments and death are ongoing. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1151 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Gitte Kristensen More articles by this author Martin Andreas Roeder More articles by this author Kasper Drimer Berg More articles by this author Johanna Elversang More articles by this author Birgitte Groenkaer Toft More articles by this author Klaus Brasso More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...